Last update Jan. 29, 2021
Very Low Risk
We do not have alternatives for P01BA02 since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
P01BA02 is Hydroxychloroquine Sulfate in ATC Code/s.Is written in other languages:
P01BA02 belongs to this group or family:
Main tradenames from several countries containing P01BA02 in its composition:
|VD||580 - 815||l/Kg|
|Tmax||1 - 2||hours|
|T½||768 - 1200||hours|
|Theoretical Dose||0.06 - 0.2||mg/Kg/d|
|Relative Dose||0.9 - 3||%|
|Ped.Relat.Dose||0.4 - 6.6||%|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is an antimalarial drug with actions similar to those of chloroquine. It is used as anti-inflammatory and immunomodulating agent in the treatment and prophylaxis of malaria, in the management of systemic and discoid lupus erythematosus, rheumatoid arthritis, porphyria cutanea tarda, sarcoidosis and various skin disorders. It is also used in prophylaxis of venous thromboembolism.
Used experimentally in the treatment of the COVID-19 coronavirus (Elavarasi 2020, SEFH 2020).
It is excreted in breast milk in clinically non-significant amount which is much lower than the dose used in infants (Peng 2019, Liu 2016, Cissoko 2010, Costedoat 2002, Ostensen 1985, Nation 1984).
Problems related to clinical features, development, vision or hearing issues have not been observed in infants whose mothers have received this medication (Peng 2019, Motta 2005 & 2002, Cimaz 2004, Tincani 2001).
When the mother takes 400 mg per day only 1 mg appears for every liter of milk, which is not considered dangerous to the infant, since a preventive dose for malaria in infants is 5 mg per kilo of weight once a week.
Several medical associations, experts and expert consensus consider the use of this medication to be compatible during breastfeeding (Hale, Sammaritano 2020, Briggs 2017, Flint 2016, Götestam 2016, Kavanaugh 2015, Schaefer 2015).
American Academy of Pediatrics states that it is usually compatible with breastfeeding medication (AAP 2001).
See below the information of these related products: